Vivo Bio Tech Limited

BSE:511509 Stock Report

Market Cap: ₹580.2m

Vivo Bio Tech Past Earnings Performance

Past criteria checks 4/6

Vivo Bio Tech's earnings have been declining at an average annual rate of -2.2%, while the Life Sciences industry saw earnings growing at 25.3% annually. Revenues have been declining at an average rate of 3% per year. Vivo Bio Tech's return on equity is 12.5%, and it has net margins of 15.9%.

Key information

-2.2%

Earnings growth rate

-6.6%

EPS growth rate

Life Sciences Industry Growth11.2%
Revenue growth rate-3.0%
Return on equity12.5%
Net Margin15.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Vivo Bio Tech makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:511509 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24468751960
30 Jun 24440261930
31 Mar 24455252020
31 Dec 23485392120
30 Sep 23491272160
30 Jun 23525252360
31 Mar 23522262370
31 Dec 22528-12470
30 Sep 22522112470
30 Jun 22497132580
31 Mar 22514222390
31 Dec 21522322720
30 Sep 21511412590
30 Jun 21556592680
31 Mar 21518572680
31 Dec 20500502470
30 Sep 20523402850
30 Jun 20512422780
31 Mar 20554443210
31 Dec 19548192270
30 Sep 19551182270
30 Jun 19554152270
31 Mar 19558223240
31 Mar 18470311720
31 Mar 17341251810
31 Mar 1628691310
31 Mar 151785980
31 Mar 141613990

Quality Earnings: 511509 has high quality earnings.

Growing Profit Margin: 511509's current net profit margins (15.9%) are higher than last year (5.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 511509's earnings have declined by 2.2% per year over the past 5 years.

Accelerating Growth: 511509's earnings growth over the past year (178%) exceeds its 5-year average (-2.2% per year).

Earnings vs Industry: 511509 earnings growth over the past year (178%) exceeded the Life Sciences industry 38.1%.

Return on Equity

High ROE: 511509's Return on Equity (12.5%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 22:09
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vivo Bio Tech Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution